Short answer
Inmune Bio, Inc. (INMB) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$5M
- +27.0% YoY · −270.9% QoQ
- EPS (diluted)
- −$0.17
- +10.5% YoY · −240.0% QoQ
Source: XBRL data from the Inmune Bio, Inc. (INMB) Q3 2026 10-Q on SEC EDGAR. USD.
Inmune Bio, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0, unchanged YoY; net loss $4.7M vs $6.5M
- Q3 operating expenses $5.0M vs $7.4M, research and development $3.2M vs $4.9M
- CORDStrom/INKmune costs $2.4M vs $1.1M, highest product-program spending
- Cash $16.3M at September 30, 2026 vs $24.8M at December 31, 2025; operating cash use $10.0M
- Near-term headwind: cash projected insufficient for one year; MAA targeted February 2027, BLA mid-2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inmune Bio, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.